- Home
- RARE vs CLSK Comparison
RARE vs CLSK Comparison
Compare RARE & CLSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | CLSK |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | CLSK |
|---|---|---|
| Price | $34.86 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $85.20 | $23.83 |
| AVG Volume (30 Days) | 1.5M | ★ 35.7M |
| Earning Date | 11-04-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | $630,598,000.00 | ★ $766,314,000.00 |
| Revenue This Year | $19.09 | $21.78 |
| Revenue Next Year | $20.62 | $17.55 |
| P/E Ratio | ★ N/A | $10.74 |
| Revenue Growth | 20.63 | ★ 102.21 |
| 52 Week Low | $25.81 | $6.45 |
| 52 Week High | $46.50 | $23.61 |
Technical Indicators
Market Signals| Indicator | RARE | CLSK |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 43.63 |
| Support Level | $32.64 | $11.15 |
| Resistance Level | $36.81 | $12.67 |
| Average True Range (ATR) | 1.60 | 1.20 |
| MACD | -0.29 | -0.13 |
| Stochastic Oscillator | 28.83 | 22.84 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About CLSK CleanSpark Inc.
Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.